Update shared on03 Sep 2025
Fair value Increased 1.17%Both the Future P/E and Net Profit Margin for Fresenius SE KGaA remained essentially stable, underpinning the marginal increase in the consensus analyst price target from €49.04 to €49.61.
What's in the News
- Fresenius is leading the EASYGEN consortium, a public-private EU-funded initiative aiming to accelerate and cost-optimize CAR-T cell therapy manufacturing, making it more accessible across Europe using modular, hospital-based platforms.
- Fresenius subsidiaries, including Helios hospitals and ironsalud in Spain, are actively offering and developing CAR-T cell therapies, with ongoing clinical trials and advanced oncology units for hematologic malignancies.
- The company raised its 2025 organic revenue growth guidance from 5%–7% (previously 4%–6%) and reaffirmed its EBIT outlook, expecting a EUR 100 million contribution from its German performance program.
Valuation Changes
Summary of Valuation Changes for Fresenius SE KGaA
- The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from €49.04 to €49.61.
- The Future P/E for Fresenius SE KGaA remained effectively unchanged, moving only marginally from 14.59x to 14.80x.
- The Net Profit Margin for Fresenius SE KGaA remained effectively unchanged, moving only marginally from 8.53% to 8.50%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.